EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Symptomatic osteonecrosis in children treated for Hodgkin lymphoma: A population‐based study in Sweden, Finland, and Denmark

Mia Giertz iD, Henri Aarnivala iD, Sascha Wilk Michelsen, Caroline Björklund, Annika Englund iD, Marika Grönroos, Lisa Lyngsie Hjalgrim, Pasi Huttunen, Tuukka Niinimäki, Eva Penno, Tuuli Pöyhönen, Päivi Raittinen und 5 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Mia Giertz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Hodgkin Disease, Osteonecrosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mary Beve's Foundation, Gerd Ahlman's Fund, Swedish Childhood Cancer Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osteonecrosis (ON) is a potentially disabling skeletal complication of cancer treatment. Although symptomatic osteonecrosis (sON) is well‐known in acute lymphoblastic leukemia (ALL), with an incidence around 6%, studies on sON in pediatric Hodgkin lymphoma (HL) are scarce. The aim of this study was to examine the incidence, risk factors, and outcome of sON in children treated for HL. Procedure A total of 490 children under 18, diagnosed with HL between 2005 and 2019 in Sweden, Finland, and Denmark were eligible for the study. Data on patient characteristics, HL treatment, and development of sON were collected from patients’ medical records. Magnetic resonance imaging scans were used to establish ON diagnosis and grade ON according to the Niinimäki grading system.

Results

Cumulative 2‐year incidence of sON among the 489 included patients was 5.5% ( n = 30). The risk for developing sON was higher for those with older age (odds ratio [OR] 1.25, 95% confidence interval [CI]: 1.05–1.49, p < .010), female sex (OR 4.45, CI 1.87–10.58, p < .001), high total cumulative glucocorticoid (GC) doses (OR 1.76, 95% CI: 1.21‐2.56, p = 0.003), and advanced HL (OR 2.19, 95% CI: 1.03‐4.65, p = .042). Four (13.3%) patients underwent major surgical procedures and 13 (43.3%) had persistent symptoms due to ON at follow‐up.

Conclusions

This study shows that sON is as common in pediatric HL as in pediatric ALL, with risk factors such as older age, female sex, high cumulative GC doses, and advanced HL. Future HL protocol development should aim to reduce the burden of ON by modifying GC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseOsteonecrosisHumansMaleFemaleChildAdolescentDenmarkFinlandIncidenceChild, PreschoolSwedenRisk FactorsFollow-Up StudiesPrognosisInfant

Stichwörter der Autor:innen

Hodgkin lymphomachildrenosteonecrosis

Autor:innen und Institutionen

  • Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
  • Department of Pediatric Oncology and Hematology, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Paediatrics, Oulu University Hospital, Oulu, Finland.
  • Research Unit of Clinical Medicine, University of Oulu, Oulu, Finland.
  • Department of Pediatric Hematology and Oncology, Department of Pediatric and Adolescence Medicine, Juliane Marie Centret, University Hospital Copenhagen, Copenhagen, Denmark.
  • Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden.

ORCID-Profile: Mia Giertz, Henri Aarnivala, Annika Englund, Susanna Ranta, Riitta Niinimäki

Förderung

  • Mary Beve's Foundation
  • Gerd Ahlman's Fund
  • Swedish Childhood Cancer Fund
  • Alma and K. A. Snellman Foundation
  • Väre Foundation for Pediatric Cancer Research
  • Danish Childhood Cancer Foundation
  • Lion's Cancer Research Fund of Middle Sweden
  • Lasten Syöpäsäätiö Väreen

Zitieren

APA

Giertz, M., Aarnivala, H., Wilk Michelsen, S., Björklund, C., Englund, A., Grönroos, M., Hjalgrim, L. L., Huttunen, P., Niinimäki, T., Penno, E., Pöyhönen, T., Raittinen, P., Ranta, S., Svahn, J. E., Törnudd, L., Niinimäki, R., & Harila, A. (2024). Symptomatic osteonecrosis in children treated for Hodgkin lymphoma: A population‐based study in Sweden, Finland, and Denmark. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31250

Vancouver

Giertz M, Aarnivala H, Wilk Michelsen S, Björklund C, Englund A, Grönroos M, et al. Symptomatic osteonecrosis in children treated for Hodgkin lymphoma: A population‐based study in Sweden, Finland, and Denmark. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31250

BibTeX
@article{Giertz2024,
  author = {Giertz, Mia and Aarnivala, Henri and Wilk Michelsen, Sascha and Björklund, Caroline and Englund, Annika and Grönroos, Marika and Hjalgrim, Lisa Lyngsie and Huttunen, Pasi and Niinimäki, Tuukka and Penno, Eva and Pöyhönen, Tuuli and Raittinen, Päivi and Ranta, Susanna and Svahn, Johan E and Törnudd, Lisa and Niinimäki, Riitta and Harila, Arja},
  title = {Symptomatic osteonecrosis in children treated for Hodgkin lymphoma: A population‐based study in Sweden, Finland, and Denmark},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31250}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche